The listing below shows our latest News Items and is updated regularly. If you wish to post a news item please select the 'Post News' button on the right. The displayed news feed starts on 1st August 2016. Older items can be found here.
To 'Post Your News' use the button at the top right.
We are pleased to present below all posts archived in 'February, 2018'. If you still can't find what you are looking for, try using the search box.
AMSBIO is a specialist life science company offering an extensive portfolio of Poly (ADP-ribose) polymerase (PARP) isozymes. In addition, AMSBIO also offer assay kits, inhibitors, recombinant histone substrates and screening / profiling services for over 10 different PARP’s.
Read the rest of entry »
OBN Launch BioForward® Conference - a unique, high-quality, international conference, focussed on creating and developing a practical roadmap for early stage, emerging, and developing companies to achieve sustainable business success and growth.
New software to deliver faster and more accurate diagnoses in genetic epilepsies is the ambition of a ground-breaking partnership between Congenica, a global provider of clinical genomics interpretation software, and FutureNeuro, the SFI Research Centre for Chronic and Rare Neurological Diseases, supported by Science Foundation Ireland. The software will be designed to work with electronic health record (EHR) systems, including the Irish electronic health record for Epilepsy, so that the entire diagnostic process, from initial DNA sequencing to determining treatment options, is available to clinicians and patients through their electronic records.
Wickham Laboratories Ltd will exhibit on Stand 408 at the Making Pharmaceuticals Europe Conference, from the 13th - 14th March 2018 in Belgium at Brussels Expo centre.
Making Pharmaceutical Europe offers a free to attend exhibition and conference featuring many companies who are involved within the pharmaceutical industry.
This will be the exhibition’s inaugural event in Europe and we are proud to be supporting the expansion of the Making Pharmaceuticals tradeshow.
Dr Lynne Murdoch, our head of microbiology, will also be contributing to the conference seminar programme with a discussion on the merits of rapid microbiological testing. This presentation, MALDI-ToF in Practice; Validated Application of a Rapid Microbiological Method, will take place on 13 March at 10:10AM, Room B of the Brussels Expo centre.
Join Dr Murdoch for this exciting discussion on MALDI-ToF as a quicker and more reliable method of microbial identification or visit Stand 408 to discuss your specific contract testin ...
Cello Health has today announced the launch of their new social media insight and analytics business, Cello Health Logic. The business, born out of Cello Health Insight’s dedicated digital division, aims to meet the need for pharmaceutical and healthcare clients to tap into and better understand the huge volume of real-world conversational data that has the potential to drive strategic decision making.
Absolute Antibody Ltd., an Oxford, UK-based company with a vision to make recombinant antibody technology accessible to all, and Kerafast Inc., a Boston, MA-based company with a mission to facilitate access to unique laboratory-made reagents, today announced a merger of the two companies.
Physiomics plc (AIM: PYC), a provider of technology-based solutions to predict the effects of cancer treatment regimens for the biopharma industry, is delighted to announce that it has been awarded a contract by a further major (global top-10) pharmaceutical client. The project, which has a value of approximately £70k, is expected to be completed during the Company’s current financial year and involves the use of Physiomics’ Virtual Tumour technology in a pre-clinical setting.
Collaborations and commercial contracts to advance company’s growth and role in Asia
The new platform combines microfluidic lab-on-a-chip technology with physiologically relevant 3D spheroids to enable formation and long-term culture of 3D multicellular tumors / organoids for drug screening and individualized chemosensitivity testing
We interviewed Paul Overton, Global Head of Business Development & Marketing at Evotec, on how the world of R&D is changing in Life Sciences and what he predicts the future holds.
OBN aims to provide sector NEWS that is relevant to our Membership. We filter information from a variety of sources, publish items ourselves and will publish items of News from our Members. Press releases about OBN can be found here.
This is an impromptu noticeboard to let people know about events, other things that are happening, perhaps lab equipment for sale etc. Just drop an email to us, email@example.com, and we will post.